GILD insider trading
NasdaqGS HealthcareGILEAD SCIENCES, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About GILEAD SCIENCES, INC.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company website: www.gilead.com
GILD insider activity at a glance
FilingIQ has scored 1,351 insider transactions for GILD since Jan 8, 2015. The most recent filing in our index is dated Apr 30, 2026.
Across the full history, 0 open-market purchases
and 344 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GILD insider trades is 66.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GILD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding GILD
Politicians who have traded GILD
Frequently asked
- How many insider trades does FilingIQ track for GILD?
- FilingIQ tracks 1,351 Form 4 insider transactions for GILD (GILEAD SCIENCES, INC.), covering filings from Jan 8, 2015 onwards. 65 of those were filed in the last 90 days.
- Are GILD insiders net buyers or net sellers?
- Across the full Form 4 history for GILD, 0 transactions (0%) were open-market purchases and 344 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GILD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GILD in?
- GILEAD SCIENCES, INC. (GILD) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $183.79B.
Methodology & sources
Every GILD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.